Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Monopar Therapeutics Inc. (MNPR)

119.05 0.00 (0.00%)
As of 9:37:20 AM EDT. Market Open.
Trade MNPR on Coinbase
Chart Range Bar
Loading chart for MNPR
  • Previous Close 119.05
  • Open 118.50
  • Bid 108.70 x 300
  • Ask 109.80 x 500
  • Day's Range 114.81 - 120.00
  • 52 Week Range 29.18 - 124.82
  • Volume 5,869
  • Avg. Volume 214,320
  • Market Cap (intraday) 799.084M
  • Beta (5Y Monthly) 1.51
  • PE Ratio (TTM) --
  • EPS (TTM) -2.20
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 126.31

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

www.monopartx.com

22

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 8/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MNPR
82.31%
S&P 500 (^GSPC)
12.69%

1-Year Return

MNPR
255.27%
S&P 500 (^GSPC)
20.32%

3-Year Return

MNPR
3,580.06%
S&P 500 (^GSPC)
76.54%

5-Year Return

MNPR
403.38%
S&P 500 (^GSPC)
75.09%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -3.89M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-5M
-4M
-3M
-2M
-1M
0

Analyst Insights

View More

Analyst Price Targets

100.00 Low
126.31 Average
119.05 Current
145.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 125 -> 128

Statistics

View More

Valuation Measures

Annual
As of 8/17/2026
  • Market Cap

    781.90M

  • Enterprise Value

    647.71M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.98

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.64%

  • Return on Equity (ttm)

    -19.50%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -17.84M

  • Diluted EPS (ttm)

    -2.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    134.3M

  • Total Debt/Equity (mrq)

    0.16%

  • Levered Free Cash Flow (ttm)

    -6.1M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

119.05 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: